Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Platelet-derived growth factor inhibitors

Platelet-activating Factor Platelet Aggregation Inhibitors Platelet-derived Growth Factor Receptor Platelet Inhibitors Platelets... [Pg.1500]

Fujio Y, Yamada F, Takahashi K, Shibata N. Responses of smooth muscle cells to platelet-derived growth factor are inhibited by herbimycin-A tyrosine kinase inhibitor. Biochem Biophys Res Commun 1993 195(1) 79—83. [Pg.288]

Katritzky, A.R. et al., QSAR studies in 1-phenylbenzimidazoles as inhibitors of the platelet-derived growth factor, Bioorg. Med. Chem., 13,6598,2005. [Pg.49]

Imatinib is an inhibitor of the protein tyrosine kinase involved with platelet-derived growth factor (Bcr-ABL). A loss of cellular control of this tyrosine kinase has been identified as a key mechanism for malignant cell growth. The ability of imatinib to inhibit Bcr-ABL provides a rationale for its use in the treatment of human cancers such as Philadelphia... [Pg.78]

Imatinib (STI571) is an inhibitor of the tyrosine kinase domain of the Bcr-Abl oncoprotein and prevents the phosphorylation of the kinase substrate by ATP. It is indicated for the treatment of chronic myelogenous leukemia (CML), a pluripotent hematopoietic stem cell disorder characterized by the t(9 22) Philadelphia chromosomal translocation. This translocation results in the Bcr-Abl fusion protein, the causative agent in CML, and is present in up to 95% of patients with this disease. This agent inhibits other activated receptor tyrosine kinases for platelet-derived growth factor receptor (PDGFR), stem cell factor (SCF), and c-kit. [Pg.1307]

Platelet aggregation different pathways of activation. Abbreviations ADR adenosine diphosphate ATP, adenosine triphosphate COX, cyclooxygenase PAI, plasminogen activator inhibitor PDGF, platelet derived growth factor. [Pg.60]

Mendel DB et al (2003) In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9 327-337... [Pg.242]


See other pages where Platelet-derived growth factor inhibitors is mentioned: [Pg.233]    [Pg.233]    [Pg.82]    [Pg.866]    [Pg.590]    [Pg.239]    [Pg.4]    [Pg.458]    [Pg.32]    [Pg.506]    [Pg.544]    [Pg.162]    [Pg.198]    [Pg.54]    [Pg.176]    [Pg.409]    [Pg.326]    [Pg.339]    [Pg.653]    [Pg.247]    [Pg.132]    [Pg.130]    [Pg.31]    [Pg.364]    [Pg.228]    [Pg.9]    [Pg.32]    [Pg.129]    [Pg.325]    [Pg.339]    [Pg.347]    [Pg.395]    [Pg.428]    [Pg.209]    [Pg.158]    [Pg.215]    [Pg.75]    [Pg.88]    [Pg.241]    [Pg.514]   


SEARCH



Factor inhibitor

Growth factor inhibitor

Growth inhibitors

Platelet inhibitors

© 2024 chempedia.info